LPCN Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -3426.15% compared to Lipocine's net margin of -49.65%. Lipocine's return on equity of -36.41% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Lipocine has a consensus price target of --, signalling upside risk potential of 355.51%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 557.2%. Given that NovaBay Pharmaceuticals has higher upside potential than Lipocine, analysts believe NovaBay Pharmaceuticals is more attractive than Lipocine.

Lipocine has a beta of 1.240, which suggesting that the stock is 24.005% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Lipocine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lipocine pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Lipocine quarterly revenues are $89.6K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Lipocine's net income of -$2.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Lipocine's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lipocine is 5.25x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -3426.15% compared to Lipocine's net margin of 25.23%. Lipocine's return on equity of -36.41% beat Pfizer's return on equity of 4.63%.

Lipocine has a consensus price target of --, signalling upside risk potential of 355.51%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.97%. Given that Lipocine has higher upside potential than Pfizer, analysts believe Lipocine is more attractive than Pfizer.

Lipocine has a beta of 1.240, which suggesting that the stock is 24.005% more volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Lipocine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.33% to investors and pays a quarterly dividend of $0.42 per share. Lipocine pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Lipocine quarterly revenues are $89.6K, which are smaller than Pfizer quarterly revenues of $17.7B. Lipocine's net income of -$2.2M is lower than Pfizer's net income of $4.5B. Notably, Lipocine's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lipocine is 5.25x versus 2.54x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -3426.15% compared to Lipocine's net margin of -2357.27%. Lipocine's return on equity of -36.41% beat Palatin Technologies's return on equity of --.

Lipocine has a consensus price target of --, signalling upside risk potential of 355.51%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than Lipocine, analysts believe Palatin Technologies is more attractive than Lipocine.

Lipocine has a beta of 1.240, which suggesting that the stock is 24.005% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Lipocine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lipocine pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Lipocine quarterly revenues are $89.6K, which are smaller than Palatin Technologies quarterly revenues of $350K. Lipocine's net income of -$2.2M is higher than Palatin Technologies's net income of -$7.8M. Notably, Lipocine's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lipocine is 5.25x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Reviva Pharmaceuticals Holdings has a net margin of -3426.15% compared to Lipocine's net margin of --. Lipocine's return on equity of -36.41% beat Reviva Pharmaceuticals Holdings's return on equity of --.

Lipocine has a consensus price target of --, signalling upside risk potential of 355.51%. On the other hand Reviva Pharmaceuticals Holdings has an analysts' consensus of $14.80 which suggests that it could grow by 695.7%. Given that Reviva Pharmaceuticals Holdings has higher upside potential than Lipocine, analysts believe Reviva Pharmaceuticals Holdings is more attractive than Lipocine.

Lipocine has a beta of 1.240, which suggesting that the stock is 24.005% more volatile than S&P 500. In comparison Reviva Pharmaceuticals Holdings has a beta of -0.023, suggesting its less volatile than the S&P 500 by 102.311%.

Lipocine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reviva Pharmaceuticals Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lipocine pays -- of its earnings as a dividend. Reviva Pharmaceuticals Holdings pays out -- of its earnings as a dividend.

Lipocine quarterly revenues are $89.6K, which are larger than Reviva Pharmaceuticals Holdings quarterly revenues of --. Lipocine's net income of -$2.2M is higher than Reviva Pharmaceuticals Holdings's net income of -$8.4M. Notably, Lipocine's price-to-earnings ratio is -- while Reviva Pharmaceuticals Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lipocine is 5.25x versus -- for Reviva Pharmaceuticals Holdings. Usually stocks with elevated PS ratios are considered overvalued.